FDA Brief

Warning letters Drugs

FDA warning letter to

Yangzhou Yulou Paper Products Co., Ltd.

High riskIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.

What happened

FDA reviewed records the company submitted after a Feb. 10, 2025, records request; there was no inspection. The records did not show that OTC products labeled sterile were rendered sterile, and they did not show identity testing of components, stability data, process validation, or adequate quality-unit procedures. FDA also said the firm agreed to recall all sterile products from the U.S. market that were within expiry.

What FDA found

  1. The firm did not show that its drug products labeled sterile were actually made sterile, and it lacked validated sterility testing and laboratory specifications.

    21 CFR 211.113(b); 21 CFR 211.160(b)
  2. The firm did not test each incoming component to confirm its identity before use in manufacturing.

    21 CFR 211.84(d)(1)
  3. The firm lacked stability studies to show its drug products remain acceptable through their labeled expiry date.

    21 CFR 211.166(a)
  4. The firm had not validated its manufacturing processes and did not show routine testing or monitoring of a key ingredient/system that was redacted in the letter.

    21 CFR 211.100(a)
  5. The firm's quality unit lacked written procedures for complaints, batch release, deviations, corrective actions, and other quality duties.

    21 CFR 211.22(d)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with corrective actions and plans addressing sterility assurance, component identity testing, stability, process validation, and quality-unit oversight. FDA also strongly recommends a qualified consultant to help with manufacturing-quality compliance.

Who should pay attention

  • U.S. distributors and retailers of imported OTC drugs
  • brands using Chinese contract manufacturers for OTC drug products
  • supplier quality teams responsible for sterility assurance and component testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk